Company profile
ARCUS BIOSCIENCES, INC.
NYSE:RCUSBiotechnology: Pharmaceutical Preparations
Drug pipeline (5)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| QUEMLICLUSTAT | phase3 | — | 8 | active |
| AFIVASTOBART | phase1 | — | 1 | active |
| EGANELISIB | phase1 | — | 1 | no active trials |
| LIGRITINIB | phase1 | — | 2 | no active trials |
| RALZAPASTOTUG | phase1 | — | 1 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (32)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07641881 | phase1 | completed | 2026-05-29 | 2026-07-03 | Arcus Biosciences, Inc. | A Bioequivalence Study Between Two Casdatifan Tablet Strengths and Food Effect Study of Casdatifan in Healthy Adult Participants |
| NCT05568095 | phase3 | completed | 2022-11-21 | 2026-08-28 | Arcus Biosciences, Inc. | A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body |
| NCT05154136 | phase1 | completed | 2021-10-20 | 2021-12-10 | Arcus Biosciences, Inc. | A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile of Etrumadenant in Healthy Adult Participants |
| NCT05536141 | phase1 | recruiting | 2022-10-26 | 2029-03-01 | Arcus Biosciences, Inc. | A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors |
| NCT05999513 | phase1 | completed | 2023-08-21 | 2023-10-31 | Arcus Biosciences, Inc. | A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers |
FDA applications (0)
No records yet.